Zobrazeno 1 - 10
of 14
pro vyhledávání: '"John C. Byrd"'
Autor:
Bridget K. Urie, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Kevin R. Coombes, Bonnie K. Harrington, Xiaoli Zhang, William C. Kisseberth, Amy J. Johnson, John C. Byrd, Cecile M. Krejsa, Christopher C. Coss, Duncan S. Russell, Heather L. Gardner, Cheryl A. London, Bart Van Lith, Todd Covey, Allard Kaptein, Michael Gulrajani
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
PLoS ONE
PLoS ONE
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani
Autor:
Stephan Stilgenbauer, Christoph Plass, Stephan M. Tanner, Albert de la Chapelle, John C. Byrd, Aparna Raval, Daniel Mertens, Christopher C. Oakes, Rainer Claus, Thomas Hielscher, Quan Xiang Wei
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e55261 (2013)
PLoS ONE
PLoS ONE
We previously reported a rare germline variant (c.1-6531) that resulted in allele-specific expression (ASE) of death-associated protein kinase 1 (DAPK1) and predisposition to chronic lymphocytic leukemia (CLL). We investigated a cohort of CLL patient
Autor:
En-Chi Hsu, Samuel K. Kulp, Po Chen Chiu, Ching-Shih Chen, John C. Byrd, Su-Lin Lee, Hsiao Ching Chuang, Chih-Chien Chou
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67149 (2013)
Although the rictor-mTOR complex (mTORC2) has been shown to act as phosphoinositide-dependent kinase (PDK)2 in many cell types, other kinases have also been implicated in mediating Ser473-Akt phosphorylation. Here, we demonstrated the cell line speci
Autor:
Craig C. Hofmeister, Michael A. Freitas, Mark R. Parthun, Samuel K. Kulp, Robert A. Baiocchi, Ching-Shih Chen, Dasheng Wang, Ryan B. Edwards, Lapo Alinari, Michael R. Grever, Melanie E. Davis, Kristie A. Blum, Derek A. West, Amy J. Johnson, David Jarjoura, Amy Lehman, Carlo M. Croce, Xiaoli Zhang, David M. Lucas, John C. Byrd
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e10941 (2010)
PLoS ONE
PLoS ONE
Background: While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or
Autor:
Nyla A. Heerema, Amy S. Ruppert, Laura Z. Rassenti, Leigha Senter, Amy J. Johnson, David E. Symer, Leslie A. Andritsos, Timothy L. Chen, William H. Towns, Amy Lehman, Arletta Lozanski, Tiina M. Järvinen, Albert de la Chapelle, Weiqiang Zhao, Brad Bolon, John C. Byrd, Kyle A. Beckwith, Gerard Lozanski, Carlo M. Croce, Erin Hertlein
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e76607 (2013)
PLoS ONE, Vol 8, Iss 10, p e76607 (2013)
Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatmen
Autor:
Sunjoo Ahn, Wolfgang Sadee, Michael R. Grever, Amy J. Johnson, David Jarjoura, Wenjun Ni, Jia Ji, Zunyan Dai, Audrey C. Papp, Mitch A. Phelps, Katherine L. Farley, Thomas S. Lin, Xiaobai Li, James T. Dalton, John C. Byrd
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13792 (2010)
PLoS ONE
PLoS ONE
Background: Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking act
Autor:
Natarajan Muthusamy, Michael C. Ostrowski, Susheela Tridandapani, Trupti Joshi, Carolyn Cheney, Latha P. Ganesan, John C. Byrd
Publikováno v:
PLoS ONE
PLoS ONE, Vol 4, Iss 1, p e4208 (2009)
PLoS ONE, Vol 4, Iss 1, p e4208 (2009)
Macrophages are important effectors in the clearance of antibody-coated tumor cells. However, the signaling pathways that regulate macrophage-induced ADCC are poorly defined. To understand the regulation of macrophage-mediated ADCC, we used human B c
Autor:
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani
Externí odkaz:
https://doaj.org/article/885fb92964b3445a99b5a10f0adb8206
Autor:
Su-Lin Lee, Chih-Chien Chou, Hsiao-Ching Chuang, En-Chi Hsu, Po-Chen Chiu, Samuel K Kulp, John C Byrd, Ching-Shih Chen
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67149 (2013)
Although the rictor-mTOR complex (mTORC2) has been shown to act as phosphoinositide-dependent kinase (PDK)2 in many cell types, other kinases have also been implicated in mediating Ser473-Akt phosphorylation. Here, we demonstrated the cell line speci
Externí odkaz:
https://doaj.org/article/b2c8fdea46454f19ba16c77a553e7492
Autor:
Erin Hertlein, Kyle A Beckwith, Gerard Lozanski, Timothy L Chen, William H Towns, Amy J Johnson, Amy Lehman, Amy S Ruppert, Brad Bolon, Leslie Andritsos, Arletta Lozanski, Laura Rassenti, Weiqiang Zhao, Tiina M Jarvinen, Leigha Senter, Carlo M Croce, David E Symer, Albert de la Chapelle, Nyla A Heerema, John C Byrd
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76607 (2013)
Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatmen
Externí odkaz:
https://doaj.org/article/6701b5761778490aa7e468949244dd8d